Series B8 November 2021

QuantuMDx secures £15m Series B follow-on investment from Vita Spring to develop diagnostic platforms.

Vita Spring provided the funding as QuantuMDx also pursues commercialisation discussions with Sansure Biotech.

£15.0MSeries B

QuantuMDx develops molecular point of care diagnostic solutions designed to empower disease control and pathogen identification. The company operates globally with strategic partnerships across multiple continents.

QuantuMDx has secured £15m in a Series B follow-on investment from Vita Spring. The proceeds will be directed towards evolving the Q-POC platform and expanding its menu of tests.

Alongside the funding, QuantuMDx has entered into discussions with Sansure Biotech regarding a cooperation agreement. The partnership aims to accelerate regional commercialisation in China and South-East Asia while optimising manufacturing processes.

From the founder

"I am very pleased to announce this equity investment today which will enable us to further evolve the Q-POC™ platform, making our system one of the most innovative, high multiplexing, molecular point of care devices in the market. Vita Spring shares our mission of developing accurate and efficient solutions to identify pathogens and diagnose diseases and so we are delighted they have chosen to invest in QuantuMDx. We are also looking forward to our close future relationship with Sansure and believe they will be an excellent partner for QuantuMDx in China as we look to increase our global footprint in Chinese and adjacent markets."

Jonathan O’Halloran

Chief Executive at QuantuMDx

Investor perspective

"We are delighted to invest in QuantuMDx, which is equipped with world class technologies to address acute and ever-growing point of care testing needs globally. We are also fortunate to have the opportunity to bridge the innovative technology and platform into the China market and look forward to working with Jonathan and his team to fully realise the potential of QuantuMDx as it enters into the commercial stage."

James Yan

Partner, Vita Spring